Based on the forecasted data, cardiovascular system medicine sales in Türkiye are projected to remain stable at 8.6% of total sales from 2024 to 2027, with a slight increase to 8.7% in 2028. The year-on-year variation shows stability with a negligible annual growth rate of 0.12% over the last two years (2027-2028). The compound annual growth rate (CAGR) over the forecasted period is approximately 0.23%.
The slight expected increase in sales percentage in 2028 may indicate a growing focus on cardiovascular health. Future trends to watch include advances in cardiovascular disease treatments, changes in public health policies, and demographic shifts such as an aging population which might drive higher demand for cardiovascular medicines.
